JR
Therapeutic Areas
Vivesto Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Cantrixil | Hematological (Blood) Cancers | Preclinical |
| Paccal Vet (Dog) | Canine Splenic Hemangiosarcoma post-splenectomy | Pilot Clinical Trial |
| Paccal Vet (Cat) | Feline Solid Tumors | Dose-Finding Study |
| Apealea (Paclical) | Platinum-sensitive Ovarian, Peritoneal, Fallopian Tube Cancer (1st relapse) | Marketed (EU) |
Leadership Team at Vivesto
EK
Erik Kinnman
Chief Executive Officer (CEO)
RM
Robert Maiorana
Acting Chief Financial Officer (CFO)
TF
Teresa Fernandez Zafra
Chief Scientific Officer
PZ
Peter Zonabend
Chairman of the Board
HH
Hege Hellström
Board Member
PR
Pål Ryfors
Board Member
RT
Roger Tell
Board Member